Congleton Jon 4

What Happened

• Jon Congleton, a director of IMMUNIC, Inc. (IMUX), received a grant of options covering 50,740 shares on June 29, 2026. The reported acquisition price is $0.00 because this is a derivative award (options), not a cash purchase or sale. The grant was conditionally approved by the board on March 27, 2026 and became effective after stockholder approval on June 29, 2026.

Key Details

• Transaction date: 2026-06-29; reported acquisition price: $0.00 (derivative grant).
• Grant size: options to purchase 50,740 shares of common stock.
• Vesting: options vest in 36 equal monthly installments beginning March 27, 2026 (monthly vesting over three years). (See footnotes F1 & F2.)
• Share ownership after transaction: not specified in the provided filing extract.
• Filing timeliness: report filed with period and filing date 2026-06-29 (no late filing indicated).

Context

• This filing documents an equity compensation grant (options), not an exercise or sale. Such awards are commonly used for director compensation and do not represent an immediate cash transaction or market sale of shares. The options only become exercisable as they vest per the monthly schedule; the filing does not indicate any immediate sale or cashless exercise.